Poljarević, Jelena

Link to this page

Authority KeyName Variants
orcid::0000-0002-6706-0281
  • Poljarević, Jelena (2)
  • Poljarevic, Jelena (1)

Author's Bibliography

Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells

Pavlović, Marijana; Tadić, Ana; Gligorijević, Nevenka; Poljarević, Jelena; Petrović, Tamara G.; Dojčinović, Biljana; Savić, Aleksandar; Radulović, Siniša

(Elsevier, 2020)

TY  - JOUR
AU  - Pavlović, Marijana
AU  - Tadić, Ana
AU  - Gligorijević, Nevenka
AU  - Poljarević, Jelena
AU  - Petrović, Tamara G.
AU  - Dojčinović, Biljana
AU  - Savić, Aleksandar
AU  - Radulović, Siniša
PY  - 2020
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/3634
AB  - Inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) showed remarkable clinical efficacy in BRCA-mutated tumors. Based on the rational drug design, derivatives of PARP inhibitor 3-aminobenzamide (3-AB), 2-amino-4-methylbenzamide (L1) and 3-amino-N-methylbenzamide (L2), were coordinated to the ruthenium(II) ion, to form potential drugs affecting DNA and inhibiting PARP enzyme. The four conjugated complexes of formula: C1 [(ƞ6-toluene)Ru(L1)Cl]PF6, C2 [(ƞ6-p-cymene)Ru(L1)Cl]PF6, C3 [(ƞ6-toluene)Ru(L2)Cl2] and C4 [(ƞ6-p-cymene)Ru(L2)Cl2], have been synthesized and characterized. Colorimetric 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay showed the highest antiproliferative activity of C1 in HCC1937, MDA-MB-231, and MCF-7 breast cancer cells. Efficiency of inhibition of PARP-1 enzymatic activity in vitro decreased in order: C2 > C4 > 3-AB>C1 > C3. ICP-MS study of intracellular accumulation and distribution in BRCA1-mutated HCC1937 revealed that C1-C4 entered cells within 24 h. The complex C1 showed the highest intracellular accumulation, nuclear-targeting properties, and exhibited the highest DNA binding (39.2 ± 0.6 pg of Ru per μg of DNA) that resulted in the cell cycle arrest in the S phase.
PB  - Elsevier
T2  - Journal of Inorganic Biochemistry
T1  - Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells
VL  - 210
SP  - 111155
DO  - 10.1016/j.jinorgbio.2020.111155
ER  - 
@article{
author = "Pavlović, Marijana and Tadić, Ana and Gligorijević, Nevenka and Poljarević, Jelena and Petrović, Tamara G. and Dojčinović, Biljana and Savić, Aleksandar and Radulović, Siniša",
year = "2020",
abstract = "Inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) showed remarkable clinical efficacy in BRCA-mutated tumors. Based on the rational drug design, derivatives of PARP inhibitor 3-aminobenzamide (3-AB), 2-amino-4-methylbenzamide (L1) and 3-amino-N-methylbenzamide (L2), were coordinated to the ruthenium(II) ion, to form potential drugs affecting DNA and inhibiting PARP enzyme. The four conjugated complexes of formula: C1 [(ƞ6-toluene)Ru(L1)Cl]PF6, C2 [(ƞ6-p-cymene)Ru(L1)Cl]PF6, C3 [(ƞ6-toluene)Ru(L2)Cl2] and C4 [(ƞ6-p-cymene)Ru(L2)Cl2], have been synthesized and characterized. Colorimetric 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay showed the highest antiproliferative activity of C1 in HCC1937, MDA-MB-231, and MCF-7 breast cancer cells. Efficiency of inhibition of PARP-1 enzymatic activity in vitro decreased in order: C2 > C4 > 3-AB>C1 > C3. ICP-MS study of intracellular accumulation and distribution in BRCA1-mutated HCC1937 revealed that C1-C4 entered cells within 24 h. The complex C1 showed the highest intracellular accumulation, nuclear-targeting properties, and exhibited the highest DNA binding (39.2 ± 0.6 pg of Ru per μg of DNA) that resulted in the cell cycle arrest in the S phase.",
publisher = "Elsevier",
journal = "Journal of Inorganic Biochemistry",
title = "Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells",
volume = "210",
pages = "111155",
doi = "10.1016/j.jinorgbio.2020.111155"
}
Pavlović, M., Tadić, A., Gligorijević, N., Poljarević, J., Petrović, T. G., Dojčinović, B., Savić, A.,& Radulović, S.. (2020). Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. in Journal of Inorganic Biochemistry
Elsevier., 210, 111155.
https://doi.org/10.1016/j.jinorgbio.2020.111155
Pavlović M, Tadić A, Gligorijević N, Poljarević J, Petrović TG, Dojčinović B, Savić A, Radulović S. Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. in Journal of Inorganic Biochemistry. 2020;210:111155.
doi:10.1016/j.jinorgbio.2020.111155 .
Pavlović, Marijana, Tadić, Ana, Gligorijević, Nevenka, Poljarević, Jelena, Petrović, Tamara G., Dojčinović, Biljana, Savić, Aleksandar, Radulović, Siniša, "Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells" in Journal of Inorganic Biochemistry, 210 (2020):111155,
https://doi.org/10.1016/j.jinorgbio.2020.111155 . .
1
14
6
14

Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells

Pavlović, Marijana; Tadić, Ana; Gligorijević, Nevenka; Poljarević, Jelena; Petrović, Tamara G.; Dojčinović, Biljana; Savić, Aleksandar; Radulović, Siniša

(Elsevier, 2020)

TY  - JOUR
AU  - Pavlović, Marijana
AU  - Tadić, Ana
AU  - Gligorijević, Nevenka
AU  - Poljarević, Jelena
AU  - Petrović, Tamara G.
AU  - Dojčinović, Biljana
AU  - Savić, Aleksandar
AU  - Radulović, Siniša
PY  - 2020
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/3713
AB  - Inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) showed remarkable clinical efficacy in BRCA-mutated tumors. Based on the rational drug design, derivatives of PARP inhibitor 3-aminobenzamide (3-AB), 2-amino-4-methylbenzamide (L1) and 3-amino-N-methylbenzamide (L2), were coordinated to the ruthenium(II) ion, to form potential drugs affecting DNA and inhibiting PARP enzyme. The four conjugated complexes of formula: C1 [(ƞ6-toluene)Ru(L1)Cl]PF6, C2 [(ƞ6-p-cymene)Ru(L1)Cl]PF6, C3 [(ƞ6-toluene)Ru(L2)Cl2] and C4 [(ƞ6-p-cymene)Ru(L2)Cl2], have been synthesized and characterized. Colorimetric 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay showed the highest antiproliferative activity of C1 in HCC1937, MDA-MB-231, and MCF-7 breast cancer cells. Efficiency of inhibition of PARP-1 enzymatic activity in vitro decreased in order: C2 > C4 > 3-AB>C1 > C3. ICP-MS study of intracellular accumulation and distribution in BRCA1-mutated HCC1937 revealed that C1-C4 entered cells within 24 h. The complex C1 showed the highest intracellular accumulation, nuclear-targeting properties, and exhibited the highest DNA binding (39.2 ± 0.6 pg of Ru per μg of DNA) that resulted in the cell cycle arrest in the S phase.
PB  - Elsevier
T2  - Journal of Inorganic Biochemistry
T1  - Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells
VL  - 210
SP  - 111155
DO  - 10.1016/j.jinorgbio.2020.111155
ER  - 
@article{
author = "Pavlović, Marijana and Tadić, Ana and Gligorijević, Nevenka and Poljarević, Jelena and Petrović, Tamara G. and Dojčinović, Biljana and Savić, Aleksandar and Radulović, Siniša",
year = "2020",
abstract = "Inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) showed remarkable clinical efficacy in BRCA-mutated tumors. Based on the rational drug design, derivatives of PARP inhibitor 3-aminobenzamide (3-AB), 2-amino-4-methylbenzamide (L1) and 3-amino-N-methylbenzamide (L2), were coordinated to the ruthenium(II) ion, to form potential drugs affecting DNA and inhibiting PARP enzyme. The four conjugated complexes of formula: C1 [(ƞ6-toluene)Ru(L1)Cl]PF6, C2 [(ƞ6-p-cymene)Ru(L1)Cl]PF6, C3 [(ƞ6-toluene)Ru(L2)Cl2] and C4 [(ƞ6-p-cymene)Ru(L2)Cl2], have been synthesized and characterized. Colorimetric 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay showed the highest antiproliferative activity of C1 in HCC1937, MDA-MB-231, and MCF-7 breast cancer cells. Efficiency of inhibition of PARP-1 enzymatic activity in vitro decreased in order: C2 > C4 > 3-AB>C1 > C3. ICP-MS study of intracellular accumulation and distribution in BRCA1-mutated HCC1937 revealed that C1-C4 entered cells within 24 h. The complex C1 showed the highest intracellular accumulation, nuclear-targeting properties, and exhibited the highest DNA binding (39.2 ± 0.6 pg of Ru per μg of DNA) that resulted in the cell cycle arrest in the S phase.",
publisher = "Elsevier",
journal = "Journal of Inorganic Biochemistry",
title = "Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells",
volume = "210",
pages = "111155",
doi = "10.1016/j.jinorgbio.2020.111155"
}
Pavlović, M., Tadić, A., Gligorijević, N., Poljarević, J., Petrović, T. G., Dojčinović, B., Savić, A.,& Radulović, S.. (2020). Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. in Journal of Inorganic Biochemistry
Elsevier., 210, 111155.
https://doi.org/10.1016/j.jinorgbio.2020.111155
Pavlović M, Tadić A, Gligorijević N, Poljarević J, Petrović TG, Dojčinović B, Savić A, Radulović S. Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. in Journal of Inorganic Biochemistry. 2020;210:111155.
doi:10.1016/j.jinorgbio.2020.111155 .
Pavlović, Marijana, Tadić, Ana, Gligorijević, Nevenka, Poljarević, Jelena, Petrović, Tamara G., Dojčinović, Biljana, Savić, Aleksandar, Radulović, Siniša, "Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells" in Journal of Inorganic Biochemistry, 210 (2020):111155,
https://doi.org/10.1016/j.jinorgbio.2020.111155 . .
1
14
6
14

Synthesis, characterization and in vitro antitumor activity of new palladium(II) complexes with (S,S)-R(2)edda-type esters

Zmejkovski, Bojana; Savic, Aleksandar; Poljarevic, Jelena; Pantelić, Nebojša Đ.; Arandelovic, Sandra; Radulovic, Sinisa; Grgurić-Šipka, Sanja; Kaluđerović, Goran N.; Sabo, Tibor

(Oxford : Pergamon-Elsevier Science Ltd, 2014)

TY  - JOUR
AU  - Zmejkovski, Bojana
AU  - Savic, Aleksandar
AU  - Poljarevic, Jelena
AU  - Pantelić, Nebojša Đ.
AU  - Arandelovic, Sandra
AU  - Radulovic, Sinisa
AU  - Grgurić-Šipka, Sanja
AU  - Kaluđerović, Goran N.
AU  - Sabo, Tibor
PY  - 2014
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/1442
AB  - Six palladium(II) complexes with (S,S)-R(2)edda-type esters ((S,S)-R2edda-type; (S,S)-eddch = (S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate, R = Me, Et, n-Pr, 1-3; (S,S)-pddch = (S,S)-propylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate, R = Et, n-Pr, 4, 5; and (S,S)-eddip = (S,S)-ethylenediamne-N,N'-di-2-propanoate, R = i-Am, 6) were synthesized, characterized by IR, NMR spectroscopy, ESI-MS and elemental analysis. DFT calculations indicate that in case of 1-4, the most stable isomers are with (S,S)- and (R,S)-configuration of nitrogen atoms, but for complex 6 (R,R)- and (R,S)-N,N'-configured isomers. Furthermore, complex 5 was obtained as (S,S)-N,N' configured isomer. Cytotoxicity study was performed against human cervical adenocarcinoma (HeLa), human alveolar basal adenocarcinoma (A549) and non-cancerous human fetal lung fibroblast (MRC-5) cell lines using colorimetric MTT assay. From the investigated palladium(II) complexes 2, 3 and 5 exhibited highest cytotoxic potential against HeLa (IC50: 28.5 +/- 3.9, 29.5 +/- 1.3 and 34.3 +/- 3.2, respectively).
PB  - Oxford : Pergamon-Elsevier Science Ltd
T2  - Polyhedron
T1  - Synthesis, characterization and in vitro antitumor activity of new palladium(II) complexes with (S,S)-R(2)edda-type esters
VL  - 80
SP  - 106
EP  - 111
DO  - 10.1016/j.poly.2014.02.026
ER  - 
@article{
author = "Zmejkovski, Bojana and Savic, Aleksandar and Poljarevic, Jelena and Pantelić, Nebojša Đ. and Arandelovic, Sandra and Radulovic, Sinisa and Grgurić-Šipka, Sanja and Kaluđerović, Goran N. and Sabo, Tibor",
year = "2014",
abstract = "Six palladium(II) complexes with (S,S)-R(2)edda-type esters ((S,S)-R2edda-type; (S,S)-eddch = (S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate, R = Me, Et, n-Pr, 1-3; (S,S)-pddch = (S,S)-propylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate, R = Et, n-Pr, 4, 5; and (S,S)-eddip = (S,S)-ethylenediamne-N,N'-di-2-propanoate, R = i-Am, 6) were synthesized, characterized by IR, NMR spectroscopy, ESI-MS and elemental analysis. DFT calculations indicate that in case of 1-4, the most stable isomers are with (S,S)- and (R,S)-configuration of nitrogen atoms, but for complex 6 (R,R)- and (R,S)-N,N'-configured isomers. Furthermore, complex 5 was obtained as (S,S)-N,N' configured isomer. Cytotoxicity study was performed against human cervical adenocarcinoma (HeLa), human alveolar basal adenocarcinoma (A549) and non-cancerous human fetal lung fibroblast (MRC-5) cell lines using colorimetric MTT assay. From the investigated palladium(II) complexes 2, 3 and 5 exhibited highest cytotoxic potential against HeLa (IC50: 28.5 +/- 3.9, 29.5 +/- 1.3 and 34.3 +/- 3.2, respectively).",
publisher = "Oxford : Pergamon-Elsevier Science Ltd",
journal = "Polyhedron",
title = "Synthesis, characterization and in vitro antitumor activity of new palladium(II) complexes with (S,S)-R(2)edda-type esters",
volume = "80",
pages = "106-111",
doi = "10.1016/j.poly.2014.02.026"
}
Zmejkovski, B., Savic, A., Poljarevic, J., Pantelić, N. Đ., Arandelovic, S., Radulovic, S., Grgurić-Šipka, S., Kaluđerović, G. N.,& Sabo, T.. (2014). Synthesis, characterization and in vitro antitumor activity of new palladium(II) complexes with (S,S)-R(2)edda-type esters. in Polyhedron
Oxford : Pergamon-Elsevier Science Ltd., 80, 106-111.
https://doi.org/10.1016/j.poly.2014.02.026
Zmejkovski B, Savic A, Poljarevic J, Pantelić NĐ, Arandelovic S, Radulovic S, Grgurić-Šipka S, Kaluđerović GN, Sabo T. Synthesis, characterization and in vitro antitumor activity of new palladium(II) complexes with (S,S)-R(2)edda-type esters. in Polyhedron. 2014;80:106-111.
doi:10.1016/j.poly.2014.02.026 .
Zmejkovski, Bojana, Savic, Aleksandar, Poljarevic, Jelena, Pantelić, Nebojša Đ., Arandelovic, Sandra, Radulovic, Sinisa, Grgurić-Šipka, Sanja, Kaluđerović, Goran N., Sabo, Tibor, "Synthesis, characterization and in vitro antitumor activity of new palladium(II) complexes with (S,S)-R(2)edda-type esters" in Polyhedron, 80 (2014):106-111,
https://doi.org/10.1016/j.poly.2014.02.026 . .
18
11
17